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Aim: To examine the relationship between cardiovascular
risk factors, cardiovascular health at baseline and predictors
of cardiovascular disease (CVD) events at 28 months in
advanced age.
Methods: A total of 108 adults in advanced age were
recruited. A standardised questionnaire, comprehensive
physical assessments, physical activity and fasting blood
samples were analysed. CVD events at follow-up were
ascertained from hospital records.
Results: Sixty-seven per cent of participants had CVD at
baseline. Physical activity (OR (95% CI): 0.99 (0.98–1.0);
P = 0.04) and high-density lipoprotein (HDL) (OR (95%
CI): 0.3 (0.09–1.0); P = 0.046) were independently
associated with CVD. The 28-month incidence rate of CVD
was 6 cases/100 person-years. Baseline diastolic BP (OR
(95% CI): 0.9 (0.9–1.0); P = 0.03) and waist circumference
(OR (95% CI): 1.06 (1.01–1.1); P = 0.01) were
independently associated with subsequent CVD events at
follow-up.
Conclusion: Physical activity and HDL levels were
inversely associated with CVD at baseline but were not
predictive of future CVD events. CVD in advanced age
warrants further investigation.
Key words: aged, cardiovascular disease, HDL, physical
activity.
Introduction
One potential impact of population ageing is increased
health-care costs particularly devoted to cardiovascular
disease (CVD). In New Zealand, between 2001 and 2003,
53% of deaths of those aged 85 years and older (also known
as advanced age) were attributable to CVD [1]. Ma¯ori, indig-
enous to New Zealand, record a higher mortality from circu-
latory diseases at a younger age [2]; the average age of first
stroke for Ma¯ori and non-Ma¯ori New Zealanders was 61
and 76 years old, respectively [3].
Cigarette smoking, obesity, diabetes, hypertension and
hyperlipidaemia are established cardiovascular risk factors
used in the Framingham risk equation. However, this equa-
tion is limited to adults up to age 75 years. The Leiden 85+
Study reported that the Framingham risk equation did not
predict CVD mortality in people of advanced age [4]. One
explanation is that total cholesterol (TC) [5] and body weight
[6] increase with age up to the sixth and seventh decade, and
then decline. Diastolic blood pressure (DBP) rises only until
50 years and decreases thereafter but systolic blood pressure
(SBP) continues to increase with age [7]. Isolated systolic
hypertension (ISH), the predominant hypertension subtype in
older adults [8], was associated with increased risk of heart
failure (HF). However, the Cardiovascular Health Study
found that the adverse relationship between ISH and HF was
observed in adults younger but not older than 78 years old
[9]. These studies suggest individuals living past the average
life expectancy may have a different mechanism of accumu-
lation of CVD risk than younger individuals and the relation-
ship between these conventional risk factors and CVD risk
may change over time.
Most studies of CVD have involved very few people of
advanced age. This study aimed to examine risk factors
associated with CVD, to determine the incidence rate of CVD
and to explore predictors of CVD events over a follow-up
period of 28 months in people of advanced age. These find-
ings will help to understand the pathophysiology of CVD in
advanced age which will illuminate the changing mechanisms
of CVD risk and guide appropriate intervention. Findings
from this study will add to the limited body of evidence of
CVD risk in advanced age.
Material and method
Study design and participants
As part of a larger cohort study (Life and Living to Advanced
Age – a cohort study in New Zealand, LILACS NZ), we
conducted a feasibility study that collected comprehensive
baseline information and hospital records over a 28-month
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period. The LILACS NZ study is a prospective cohort study
aiming to examine a broad range of health, socioeconomic
and environmental factors related to independence in
advanced age.
In the feasibility study, 186 eligible older adults were identi-
fied from three North Island locations (rural and urban) in
New Zealand through local general practitioners and per-
sonal contact of local health services personnel. Of these,
112 (60%) respondents (33 Ma¯ori aged 75–79 years and 79
non-Ma¯ori aged 85 years) were recruited between January
and August 2008; four withdrew consent (Figure 1). The
sample size was based on available funding. We recruited
younger Ma¯ori because of an 8-year disparity in longevity
[2] and the likelihood of death in the subsequent year being
equivalent for all participants (P90 from 2001 census
STATS NZ) considering the excess level of disability at
younger age for Ma¯ori [2]. The Multi-Region Ethics Com-
mittee, Ministry of Health New Zealand approved the
study in June 2007. All study participants provided written
informed consent.
Measures
Data collection was completed in three phases. First, inter-
viewers administered face-to-face standardised question-
naires that collected sociodemographic, health behaviours,
medical history and physical activity determined using the
validated Physical Activity Scale for the Elderly (PASE) [10].
A higher PASE score indicates an increased level of physical
activity. Medications were viewed and recorded by trained
interviewers. Financial situation was gauged with specific
questions: ‘Thinking of your money situation right now,
would you say that you are comfortable; have just enough to
get along on; cannot make ends meet?’
Second, a standardised physical assessment was performed,
including anthropometric measures, blood pressure (BP),
electrocardiogram (ECG) and echocardiographic assessment
of the left ventricular mass (LVM). Third, fasting blood
samples were collected.
All echocardiographic images were digitally obtained using a
portable echocardiography machine (Sonosite Micro Maxx,
USA) according to a standardised protocol by trained
research sonographers. Transthoracic echocardiographic
images were acquired in standard planes according to the
American Society of Echocardiography (ASE) guidelines.
LVM was calculated according to the ASE formula [11] and
was indexed to height to the power of 2.7 (Ht2.7) [12].
Clinically manifest CVD was defined as the presence of myo-
cardial infarction, stroke, coronary artery bypass grafting,
peripheral artery bypass grafting, congestive heart failure,
percutaneous coronary intervention, angina, intermittent
claudication, or hospital admission due to CVD up to and
including the time of recruitment. This information was
ascertained by self-report through face-to-face interviews and
from review of hospitalisation records supplied by a nation-
ally held register of all hospitalisations. A similar process was
carried out to ascertain the presence of hypertension; verified
from medication records, self-report and sitting assessments
of BP (an average of three readings of 140/90 mmHg or
ISH SBP  140 mmHg, DBP < 90 mmHg); type 2 diabetes,
fasting serum glucose7.0 mmol; and dyslipidaemia, abnor-
mal fasting serum lipids according to the NZ Heart Founda-
Figure 1: Diagram for recruitment, response and completion rate.
Number of age-eligible older adults invited to
participate, n = 186
Agreed and consented, n = 112
Completed, n = 108
Completed questionnaire,
n = 108
Died after completion of
questionnaire, n = 1
Had physical assessments,
n = 103
Gave blood sample, n = 90
Withdrew, n = 4
Decline, n = 74
- Personally or family refused, n = 65
- Died before enrolment, n = 4
- No response to invitation, n = 4
- Coordinator excluded because of ill-health,  n = 1
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tion recommendation [13]. Subsequent CVD events were
ascertained from hospitalisation records from September
2008 to December 2010.
Statistical analysis
Descriptive statistics are presented for all variables. Continu-
ous data with a normal distribution (as determined using
histogram and box-plots) are presented as means and stand-
ard deviations (SD); with medians and interquartile ranges
for variables with a non-normal distribution. Age and ethnic-
ity were linked by the sampling design; the Ma¯ori partici-
pants’ age varied whereas non-Ma¯ori were all aged 85 years.
Logistic regression models were constructed to determine the
association between CVD and CVD risk factors (i.e. physical
activity levels, body mass index (BMI), waist circumference
(WC), waist-to-hip ratio (WHR), SBP and DBP, serum
glucose, TC, triglycerides (TG), high-density lipoprotein
(HDL), low-density lipoprotein (LDL), TC/HDL ratio and
LVM/Ht2.7) adjusting for sex, age-ethnicity, smoking status
and potential confounders (i.e. relevant medications to the
variables of interest: BP-lowering, glucose-lowering and
lipid-lowering medications); 13 models were constructed. An
interaction term (variable of interest ¥ age-ethnicity) was
added to the pertinent regression model to determine the
effect of age-ethnicity on the association between CVD and
the variable of interest. The analyses found that the associa-
tions between CVD and variables of interest were the same
for both age-ethnic groups. Variables associated with CVD at
P  0.2 from the 13 individual models were selected for
inclusion in the final regression model. Inclusions of inde-
pendent variables in the models are kept within the criterion
of 10 : 1 ratio of outcome events-to-independent variables. A
P-value of <0.05 was considered statistically significant. The
incidence rate of CVD over a follow-up period of 28 months
was calculated as the ratio of new cases to the number of
participants who did not have CVD at baseline. Logistic
regression models were used to examine determinants of
subsequent CVD events including all risk factors adjusting
for age-ethnicity, baseline CVD and relevant medications to
the variables of interest as described above. Variables associ-
ated with subsequent CVD events at P  0.2 were selected
for inclusion in the final regression model. Statistical analyses
were performed with SPSS 18.0 for Windows.
Results
Participants
One hundred and twelve participants were recruited
(response rate 60%): 33 Ma¯ori (mean age 76.6, SD = 1.8)
and 79 non-Ma¯ori (mean age 85.2, SD = 0.6); 56% were
women. More than half (53%) were widowed, 38% were
married/partnered, 6% were divorced/separated, and 3%
had never married. Most participants lived in a private resi-
dence (86%), the remainder living in a retirement village
(6%), rest home (low level dependency long-term residential
care) (4%) or on a marae (tribal based housing) (4%). Three-
quarters had received secondary (38%) or tertiary (36%)
education. Most participants were financially ‘comfortable’
(86%), 11% ‘just have enough to get along’, and 3% ‘could
not make ends meet’.
Cardiovascular risk factors and CVD
Half of the participants (n = 55, 51%) had never smoked
cigarettes, 92 (85%) had dyslipidaemia, 91 (84%) had hyper-
tension, 22 (20%) had type 2 diabetes, and 27% had a BMI
30.0 kg/m2. Seventy-two (67%) participants had CVD at
baseline. The breakdowns of baseline CVD events are shown
in Figure 2. Table 1 reports the clinical characteristics in
relation to cardiovascular risk factors. In univariate analyses,
no variables differed between those with and without CVD
except for WC which was lower (P = 0.02) and HDL higher
(P = 0.04) in those without than with CVD. Physical activity
levels were higher in those without CVD and not on any
prescribed medications than those with CVD and on pre-
scribed medication (Figure 3).
Risk factors associated with CVD
Variables associated with CVD at P  0.2 were physical
activity (PASE score), HDL, BMI, WC and LVM (LVM/
Ht2.7). A final regression model was constructed from these
variables to examine independent association of relevant
risk factors with CVD, controlling for sex, age-ethnicity
and smoking status. Owing to the strong correlations
between BMI, WC and HDL (P < 0.001), they were entered
into separate models (Table 2). The first three models in
Table 2 show that physical activity level was associated
with CVD after controlling for sex, age-ethnicity, smoking
status, LVM, and HDL (Model 1), BMI (Model 2) and WC
(Model 3).
Limiting the covariate list to conventional cardiovascular risk
factors associated with CVD at P 0.2 (HDL, BMI and WC)
and controlling for sex, age-ethnicity and smoking status, we
found that HDL was independently associated with CVD
(OR (95% CI): 0.3 (0.1–1.0); P = 0.04) but not BMI (OR
(95% CI): 1.08 (1.0–1.2); P = 0.1) or WC (OR (95% CI):
1.03 (1.0–1.06); P = 0.1). Although SBP was not associated
with CVD at P  0.2, it is an important CVD risk factor, so
the association between HDL and CVD was further control-
led for SBP. HDL remained associated with CVD independ-
ent of sex, age-ethnicity, smoking status and SBP (Table 2,
Model 4).
CVD events during follow-up
During the follow-up period, 12 (17%) participants with
CVD at baseline had recurrent events, five (14%) partici-
pants who did not have CVD at baseline had new events; 31
participants remained CVD-free and 60 participants did not
have a recurrent CVD event. The breakdowns of baseline
CVD events at 28 months are shown in Figure 2. The
28-month incidence rate of CVD was 6 cases per 100 person-
years. No association was found between baseline CVD and
CVD events during follow-up period (Table 2). Baseline risk
factors associated with CVD events during follow-up period
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at P  0.2 were PASE score, DBP, BMI, WC, WHR, HDL,
TG and TC/HDL ratio. A final regression model was con-
structed from these variables to examine independent asso-
ciation between baseline risk factors and subsequent CVD,
controlling for age-ethnicity and baseline CVD. DBP was
inversely and WC was positively associated with subsequent
CVD events (Table 2, Model 6). Physical activity level
(Model 7) and HDL (Model 8) demonstrated an inverse but
not statistically significant relationship with subsequent
CVD. Table 3 shows the baseline cardiovascular risk factors
for each of the four groups of participants.
Discussion
In this study of people in advanced age, two-thirds of the
participants had clinically manifest CVD at the time of the
baseline assessment. Controlling for conventional CVD risk
factors and LVM, we found that physical activity was
inversely associated with CVD. Habitual physical activity is
Figure 2: The breakdown of CVD events at baseline and at 28 months.
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period. The five ‘New CVD’ cases are CHF (n = 2), cerebrovascular disease (n = 1), IC (n = 1) and pacemaker implantation (n = 1).
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associated with reduced CVD risk [15,16]; however, the
presence of CVD may in turn affect the level of physical
activity achieved. Heart failure and stroke limit physical
function and cause disability [17,18]. Comorbidities restrict
physical function leading to functional decline in older adults
[19]. Participants who had CVD and were on five or more
prescribed medications (a reasonable indication for presence
of comorbidities) performed less physical activity. The cause
and effect relationship between physical activity and CVD
could not be determined in this study but is likely to operate
in both directions.
In examining the lipid profile, this study found HDL was
inversely associated with CVD. This finding differs from the
current evidence that TC/HDL ratio best predicts cardiovas-
cular outcomes in adults [20]. One reason why HDL is more
important than other lipid parameters in advanced age may
be that the relationship between cholesterol levels and nutri-
tional status differs in old age. In older patients (mean age 68
years) with stable chronic heart failure, cholesterol levels
were positively correlated with pre-albumin levels, suggesting
that cholesterol levels indicate nutritional status [21]. In our
study sample, we found risk of undernutrition was prevalent
[22]. Longitudinal studies have shown that cholesterol levels
decline after age 65 years [23]. The chain effect of ageing and
poorer nutritional status leading to declining cholesterol
levels may suggest that the predictive value of the TC/HDL
ratio observed in younger adults is not as good a predictor of
CVD risk in advanced age. HDL may be more useful.
Other studies have shown a positive relationship between
HDL and functional performance in community-dwelling
older people [24,25]. HDL has been suggested to be a well-
being index [25]. Our study found that physical activity was
associated with CVD, but HDL did not moderate this asso-
ciation. Physical activity is closely related to health status in
older adults [19]. However, life-time habitual physical activ-
ity protects against CVD risk [15,16] by raising HDL levels.
At advanced age, where comorbidities are common, is
decreased HDL a cause or consequence of reduced physical
activity? The vicious cycle between physical activity, HDL
and CVD in advanced age remains under-explored.
In our study, a lower DBP and a higher WC at baseline were
associated with CVD events during the follow-up period;
baseline CVD was not associated with subsequent CVD
events. Our finding of a positive association between WC and
CVD risk is in line with other epidemiological studies [26]
Table 1: Clinical characteristics in relation to cardiovascular risk factors of study participants
All (n = 108) No CVD (n = 36) Yes CVD (n = 72)
Age-ethnicity
Ma¯ori (75–79 years) 33 (31%) 10 (28%) 23 (68%)
Non-Ma¯ori (85 years) 75 (69%) 26 (72%) 49 (32%)
Sex: Men 48 (44%) 13 (36%) 35 (49%)
PASE†, median (IQR) 84 (86) 96 (111) 80 (63)
BMI, median (IQR) 27.1 (7.1) 24.7 (5.6) 27.4 (8.4)
Waist circumference (cm), mean (SD) 95 (15) 91 (14) 97 (16)*
Waist-to-hip ratio, mean (SD) 0.9 (0.08) 0.9 (0.09) 0.9 (0.08)
Fasting serum glucose (mmol/L), median (IQR) 5.2 (0.9) 5.3 (1.1) 5.2 (0.8)
SBP (mmHg), mean (SD) 151 (21) 153 (18) 150 (23)
DBP (mmHg), mean (SD) 83 (12) 84 (12) 82 (12)
TC (mmol/L), mean (SD) 5.0 (1.1) 5.3 (1.0) 4.9 (1.1)
Triglycerides (mmol/L), median (IQR) 1.2 (0.6) 1.3 (0.7) 1.2 (0.6)
HDL (mmol/L), mean (SD) 1.5 (0.4) 1.6 (0.4) 1.4 (0.7)*
LDL (mmol/L), mean (SD) 2.9 (0.9) 3.1 (1.0) 2.8 (0.9)
TC/HDL ratio, median (IQR) 3.5 (1.3) 3.6 (1.4) 3.6 (1.3)
Normal ECG‡, n (%) 54 (53) 18 (53) 36 (54)
LVM/Ht2.7 (g/m2.7), median (IQR) 40.1 (28.5) 36.9 (17.3) 43.0 (31.2)
On pharmacotherapy in relation to the cardiovascular system§ 88 (81%) 22 (61%) 66 (92%)
Number of medication indicated for the cardiovascular system:
None 20 14 6¶
1 24 7 17
2 14 3 11
3 22 7 15
4 15 4 11
5 9 1 8
6 3 – 3
7 1 – 1
*P < 0.05. †Seven participants had a score of zero: three were wheelchair-bound, and four were in a rest home. Excluding these seven participants, the median (IQR) was 100 (85), ranges
22–282. Since it is possible to have a zero score for this instrument (questionnaire), the seven participants (6% of the total study sample) with a PASE score of zero were kept in the analysis.
‡The most common abnormality on the ECG was bundle branch block (n = 17), LV hypertrophy (n = 13), atrial fibrillation (n = 12; there were another 22 self-reported atrial fibrillation), old
myocardial infarction (n = 8). Note: two participants had two abnormalities on the ECG and one participant had three abnormalities on the ECG. §The most commonly-prescribed medication
indicated for the cardiovascular system was aspirin (n = 53; No CVD = 12, Yes CVD = 41), followed by beta blocking agents (n = 40) and ACE inhibitors/angiotensin II antagonists (n = 40),
diuretics (n = 30) and lipid-lowering medications (n = 29; No CVD = 8, Yes CVD = 21), cardiac therapy (i.e. organic nitrates, digitalis glycosides, antiarrhythmics; n = 20), calcium channel
blockers (n = 19) and warfarin (n = 13). ¶Of these 6 participants, 2 self-reported CVD and not being on prescribed medication. The remaining 4 had confirmed CVD from hospital records, 2 did
not have medication listed in the questionnaire and 2 were taking medications (metformin, allopurinol, omeprazole and lucozade) not indicated for a heart condition. BMI, body mass index; CVD,
cardiovascular disease; DBP, diastolic blood pressure; HDL, high density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; LVM, left ventricular mass; PASE, Physical Activity Scale
for the Elderly; SBP, systolic blood pressure; SD, standard deviation; TC, total cholesterol.
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suggesting indices of abdominal obesity are more appropriate
in predicting CVD risk than BMI. In the Atherosclerosis Risk
in Communities (ARIC) study of more than 760 adults (mean
age 57 years), hypertension, hyperlipidaemia, diabetes,
smoking, physical inactivity and ECG established left ven-
tricular hypertrophy were associated with increased risk of
recurrent CVD [27]. We do not have a precise explanation
for the inverse association between DBP and CVD risk. In the
Leiden 85+ Study, low DBP and SBP are associated with a
low cardiac index and a low stroke volume index [28]. There
is evidence that low BP may be a stronger predictor of poor
CVD and other adverse outcomes than high BP [29]. With
regards to physical activity, there may be a trend towards
lower physical activity levels among those with recurrent
CVD than with those who remain CVD-free during the
follow-up period (Table 3). HDL levels are in the direction of
conferring protection from subsequent CVD. Nevertheless,
our study did not have enough power to be certain if low
levels of physical activity and HDL predict subsequent CVD
events.
Seventeen participants had at least one CVD event during
the follow-up period; five new cases and 12 recurrent
cases. Participants who had CVD during the follow-up period
appear to have a less favourable baseline cardiovascular
health profile. The 28-month incidence rate of CVD was 6/100
person-years. In the Cardiovascular Health Study, the 5-year
incidence rates of coronary heart disease for Caucasian men
and women aged 85 and over were 63/1000 and 19/1000
person-years respectively [30]. Owing to the small number, we
did not compare baseline CVD risk factors between the four
different CVD groups at follow-up and we did not calculate
a sex-specific incidence rate of CVD. A larger prospective
Figure 3: PASE score in four different groups of CVD status
and medications.
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Table 2: Logistic regression models examining
cardiovascular risk factors associated with CVD in
advanced age
Dependent variable: Baseline CVD
Model† List of independent variables Odds ratio (95% CI) P-value
1 PASE score (change of 10-unit) 0.90 (0.80–1.00) 0.03
LVM 1.03 (1.00–1.07) 0.2
HDL§ 0.50 (0.10–2.06) 0.3
2 PASE score (change of 10-unit) 0.90 (0.80–1.00) 0.01
LVM 1.02 (1.00–1.06) 0.2
BMI 1.07 (0.90–1.20) 0.3
3 PASE score (change of 10-unit) 0.90 (0.80–1.00) 0.01
LVM 1.03 (1.00–1.06) 0.2
WC 1.02 (1.00–1.07) 0.4
4 HDL§ 0.30 (0.09–1.00) 0.046
SBP 1.00 (1.00–1.01) 0.1
Dependent variable: CVD events at 28-month follow-up
Model†† List of independent variables Odds ratio (95% CI) P-value
5 Baseline CVD 1.20 (0.30–4.50) 0.8
DBP 0.90 (0.90–1.00) 0.04
BMI 1.08 (1.00–1.20) 0.1
6 Baseline CVD 1.05 (0.30–4.00) 0.9
DBP 0.90 (0.90–1.00) 0.03
WC 1.06 (1.01–1.10) 0.01
7 Baseline CVD 1.30 (0.40–4.50) 0.7
DBP 0.90 (0.90–1.00) 0.04
PASE score (change of 10-unit) 0.90 (0.80–1.04) 0.172
8 Baseline CVD 0.70 (0.20–2.80) 0.6
DBP 0.90 (0.90–1.00) 0.03
HDL§ 0.20 (0.02–1.20) 0.08
PASE score (change of 10-unit) 0.90 (0.80–1.04) 0.1
†All models controlled for sex, age-ethnicity and smoking status. ††All models controlled for
age-ethnicity and baseline CVD. BP-lowering medication was not included in the models
because all participants with CVD events at follow-up were on BP-lowering medication.
§Lipid-lowering medication was not included in the model because it was found to have no
apparent association with HDL levels. Lipid-lowering medications are generally indicated for
hyperlipidaemia with limited effect on HLD levels [14]. BMI, body mass index; CVD,
cardiovascular disease; DBP, diastolic blood HDL, high density lipoprotein; LVM, left ventricular
mass; PASE, Physical Activity Scale for the Elderly; SBP, systolic blood pressure; WC, waist
circumference.
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cohort study will allow a sex- and ethnic-specific incidence
rate of CVD and reveal determinants for subsequent CVD in
advanced age.
Interestingly, our study did not find an association between
SBP and CVD. Two-thirds of the participants were on medi-
cations affecting the BP. The pharmacotherapy could have
controlled their BP, alleviating the impact of SBP on CVD
risk. Those with low BP may represent a group with low
cardiac output and thus be at increased mortality risk
because of their cardiac disease; they may have died and
therefore not be in the study. Conversely, studies of people in
advanced age have shown a non-linear relationship between
BP and all-cause mortality [31]. The lowest hazard ratio for
adverse outcomes was at SBP 140 mmHg [32], suggesting the
optimal BP for these people may be higher than currently
recommended.
It is somewhat surprising we did not find an association
between LVM and CVD or subsequent CVD events. We
speculate this may be because increasing LVM with ageing is
part of the compensatory mechanism, in conjunction with
increased BP, to overcome arterial stiffness.
The current observational study has limitations. It did not
allow causal attribution of CVD to physical activity or HDL.
The small sample could not be stratified by CVD status and
use of prescribed medications. Additionally, the healthy sur-
vivor effect may apply in this study as frailer older people
probably did not survive to an advanced age. Since our
follow-up information was constrained by being limited to
hospitalisation records only, we might have missed CVD
cases not leading to hospitalisation, such as episodes of
angina. This, however, will lead to under-reporting rather
than over-reporting of CVD. We did not include sociodemo-
graphic factors, which are potential confounders, in our
analyses. With limited data, findings from this observational
study cannot be generalised to those of advanced age in NZ;
cautious interpretation of the findings is needed.
The LILACS NZ, a prospective cohort study initiated in
March 2010, has recruited 937 participants at baseline and
will attempt to follow the sample every year for up to 15
years. The larger sample size will minimise type I error and
the prospective nature will allow a snapshot of the cause and
effect relationship between risk factors and CVD outcome in
advanced age.
Conclusion
In this sample of people in advanced age, two-thirds had
clinical evidence of CVD. Of the conventional cardiovascular
risk factors examined, HDL was inversely associated with
CVD. The inverse association between level of physical activ-
ity and CVD risk may persist into advanced age but reverse-
causality may be present. The LILACS NZ study will confirm
these findings.
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Table 3: Baseline cardiovascular risk factors of study participants with and without a CVD event during the follow-up period
Remain CVD free (n = 31) No recurrent CVD (n = 60) Yes recurrent CVD (n = 12) New CVD (n = 5)
Age-ethnicity, n
Ma¯ori (75–79 years) 9 20 3 1
Non-Ma¯ori (85 years) 22 40 9 4
PASE, median (IQR) 111 (111) 84 (62) 55 (46) 88 (80)
Glucose, median (IQR) 5.3 (1.2) 5.2 (0.9) 5.3 (0.9) 5.9 (2.8)
SBP, mean (SD) 151 (17) 151 (23) 147 (23) 172 (10)
DBP, mean (SD) 86 (11) 83 (12) 77 (12) 74 (17)
BMI, median (IQR) 24.7 (5.6) 27.0 (9.0) 28.3 (8.5) 27.8 (12.7)
WC, mean (SD) 89.6 (12.1) 95.7 (15.6) 104.4 (14.8) 101.7 (22.6)
WHR, mean (SD) 0.9 (0.1) 0.9 (0.1) 0.9 (0.09) 0.9 (0.2)
TC, mean (SD) 5.3 (1.03) 5.0 (1.1) 4.4 (1.0) 5.6 (0.7)
TG, median (IQR) 1.3 (0.7) 1.2 (0.5) 1.3 (0.9) 2.0 (0.4)
HDL, mean (SD) 1.6 (0.4) 1.4 (0.4) 1.3 (0.3) 1.3 (0.4)
LDL, mean(SD) 3.1 (1.0) 2.9 (0.9) 2.4 (0.8) 3.4 (0.9)
TC/HDL ratio, median (IQR) 3.3 (1.2) 3.6 (1.3) 3.1 (2.3) 4.2 (3.7)
LVM/ht2.7, median (IQR) 36.5 (18.1) 40.2 (29.0) 46.3 (35.2) 40.4 (-)
Atrial fibrillation, n (column %) 5 (16%) 19 (32%) 8 (67%) 2 (40%)
BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL, high density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; LVM, left ventricular mass;
PASE, Physical Activity Scale for the Elderly; SBP, systolic blood pressure; SD, standard deviation; TC, total cholesterol; TG, triglyceride; WC, waist circumference; WHR, waist-to-hip ratio.
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Key Points
• Two-thirds of people in advanced age had
clinically manifest CVD.
• Physical activity and HDL were inversely associ-
ated with CVD risk.
• The 28-month incidence rate of CVD was 6 per
100 person-years.
• Baseline DBP and WC were independently associ-
ated with subsequent CVD events at 28 months.
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